Cindy Luo, PA | UniHealth

Offices

2 locations · Stanford Health Care · 3,152 clinicians in this group

Looking this up.

Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.

Plans that list them

1 plan · 1 carrier

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Cindy Luo’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

Sort by

Plans whose provider directory lists this clinician

SCAN Strive (HMO C-SNP)	SCAN Health Plan	Listed	Oct 3, 2026

California Medical Board record

Licence C52838 · Cancelled

Licence status: Cancelled · since 2007 · Georgetown University School of Medicine. Board flags: Admin Action By Other State/Fed Gov'T.

License has been voluntarily canceled, or the license has been expired for at least five years and has not been renewed. No practice is permitted.

Matched on the licence number without its letter prefix; check the name before relying on it.

Public record actions

Sort by

Actions the Medical Board of California publishes for this licence

2011-07-07	Action in another state or by a federal agencyDiscipline	A letter of concern was issued by north carolina board based on action taken by virginia board of medicine. · North carolina medical board
2010-08-26	Action in another state or by a federal agencyDiscipline	Effective 08/19/10 conditions placed on virginia medical license. effective 08/26/10 consent order/agreement terminated - license restored to full and unrestricted status. · Virginia board of medicine

Hospitals they work in

1 hospital

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend it
Overall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024

See every measure and the patient survey for Stanford Health Care

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Sort by

Every scored measure at Stanford Health Care

Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths	5.31 (4.24 to 6.37) · 8,661 cases	Worse	Jul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits	14.1 (12.7 to 15.7) · 2,191 cases	Worse	Jan 2024 – Dec 2024
Postoperative respiratory failure rateComplications and deaths	4.08 (1.95 to 6.21) · 5,296 cases	Better	Jul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections	0.317	Better	Oct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections	0.446	Better	Oct 2024 – Sep 2025
SSI - Colon SurgeryInfections	0.241	Better	Oct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits	0.7 (0.6 to 0.9) · 3,348 cases	Better	Jan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths	1.06 (0.45 to 1.67) · 5,374 cases	No different	Jul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths	0.86 (0.72 to 1)	No different	Jul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths	166.09 (137.88 to 194.3) · 470 cases	No different	Jul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths	1.1 · 192 cases	None	Jul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths	6.4 · 146 cases	None	Jul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths	9.7 · 253 cases	None	Jul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths	6.3 · 880 cases	None	Jul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths	10.3 · 935 cases	None	Jul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths	8.7 · 501 cases	None	Jul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths	2.1 · 7,730 cases	None	Jul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths	0.13 (0 to 0.27) · 20,799 cases	No different	Jul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths	0.28 (0.14 to 0.43) · 23,182 cases	No different	Jul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths	0.94 (0.2 to 1.68) · 5,694 cases	No different	Jul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths	2.36 (1.54 to 3.19) · 7,846 cases	No different	Jul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths	5.2 (3.76 to 6.64) · 5,603 cases	No different	Jul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths	1.38 (0.23 to 2.53) · 2,211 cases	No different	Jul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths	0.52 (0.21 to 0.83) · 19,915 cases	No different	Jul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths	3.6 · 416 cases	None	Apr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections	0.869	No different	Oct 2024 – Sep 2025
MRSA BacteremiaInfections	0.857	No different	Oct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections	0.368	No different	Oct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits	16.2 · 247 cases	None	Jul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits	20.5 · 1,021 cases	None	Jul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits	47.8 · 258 cases	None	Jul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits	-1.6 · 990 cases	None	Jul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits	20.8 · 976 cases	None	Jul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits	16.5 · 959 cases	None	Jul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits	5.2 (4.4 to 6.2) · 2,191 cases	No different	Jan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits	5.1 · 425 cases	None	Jul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits	9.6 · 158 cases	None	Jul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits	19.6 · 183 cases	None	Jul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits	12.7 (10.4 to 15.4) · 4,578 cases	No different	Jan 2022 – Dec 2024

What patients said (6,810 patients answered, 25% of those asked)

Sort by

Patient survey stars by topic at Stanford Health Care

Cleanliness	4
Nurse communication	4
Doctor communication	4
Communication about medicines	3
Discharge information	4
Overall hospital rating	4
Quietness	2
Recommend hospital	5

Sort by

Share of patients giving the best answer at Stanford Health Care

Room was "always" clean	75%
Nurses "always" communicated well	82%
Doctors "always" communicated well	81%
Staff "always" explained	63%
Yes, staff "did" give patients this information	89%
Yes, staff "did" give patients information about help after discharge	89%
Doctors "always" explained things so they could understand	76%
Doctors "always" listened carefully	80%
Doctors "always" treated them with courtesy and respect	87%
Patients who gave a rating of "9" or "10" (high)	79%
Staff "always" explained new medications	76%
Nurses "always" explained things so they could understand	77%
Nurses "always" listened carefully	79%
Nurses "always" treated them with courtesy and respect	88%
"Always" quiet at night	53%
"YES", patients would definitely recommend the hospital	83%
Staff "always" explained possible side effects	50%
Yes, staff "did" give patients information about possible symptoms	90%

Original Medicare doctor bills

$2,767

Medicare paid this office $2,767 for 33 people. Most of that is long return visits and Botox.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Sort by

Largest Original Medicare bills

Long return visit (40+ min)	16	$1,553	$97

Who their Medicare patients are

33 Original Medicare patients in 2024. Average age 74 · Women 52% · Health risk score 2.99. Sicker patients than 9 in 10 peers; the typical physician assistant clinician is at 1.31.

Conditions among them: High blood pressure 75% · Cancer 45% · Coronary heart disease 36%.

The office billed $7,173, Medicare allowed $3,919 and paid $2,767; for 45 services of 6 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Sort by

Original Medicare by year

2024	33	45	74	2.99	$7,173	$2,767
2023	139	165	75	2.53	$23,206	$12,240
2022	41	47	76	2.52	$7,275	$4,437
2019	148	38,435	76	2.94	$1,640,390	$412,528
2018	227	69,579	75	2.34	$2,578,920	$638,812
2017	211	56,730	76	2.52	$1,815,320	$375,786

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 6 services

Sort by

Original Medicare services billed in 2023

Long return visit (40+ min)	52	$6,137	$108
Long return visit (40+ min)	15	$1,639	$109
Return visit (30+ min)	23	$1,572	$68
Return visit (30+ min)	14	$1,050	$75
Short return visit (20+ min)	17	$807	$47
Short return visit	12	$325	$27

2022: 1 service

Sort by

Original Medicare services billed in 2022

Long return visit (40+ min)	26	$3,242	$112

2019: 14 services

Sort by

Original Medicare services billed in 2019

Injection, denosumab, 1 mg	13	$32,470	None
Injection, darbepoetin alfa, 1 microgram (non-esrd use)	14	$22,356	None
Return visit (30+ min)	125	$19,153	$83
Injection, ferric carboxymaltose, 1 mg	13	$12,068	None
Administration of chemotherapy into vein, 1 hour or less	26	$6,592	$124
Long return visit (40+ min)	15	$2,055	$114
Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	121	$1,904	$8
Short return visit (20+ min)	15	$965	$48
Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle	13	$858	$27
Injection of additional new drug or substance into vein	12	$764	$14
Injection of drug or substance under skin or into muscle	31	$699	$14
Injection of drug or substance into vein	14	$682	$34
Injection, dexamethasone sodium phosphate, 1 mg	13	$21	None
Injection, diphenhydramine hcl, up to 50 mg	11	$10	None

2018: 16 services

Sort by

Original Medicare services billed in 2018

Injection, ferric carboxymaltose, 1 mg	30	$28,634	None
Return visit (30+ min)	192	$28,461	$78
Injection, denosumab, 1 mg	11	$18,740	None
Administration of chemotherapy into vein, 1 hour or less	30	$9,825	$123
Injection, palonosetron hcl, 25 mcg	13	$5,129	None
Short return visit (20+ min)	35	$4,347	$57
Long return visit (40+ min)	30	$3,547	$114
Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	155	$3,490	$9
Injection of drug or substance into vein	33	$2,047	$39
Injection of additional new drug or substance into vein	23	$1,802	$15
Injection of drug or substance under skin or into muscle	32	$1,324	$17
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	11	$1,181	$79
Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle	13	$947	$24
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less	11	$855	$27
Injection, dexamethasone sodium phosphate, 1 mg	21	$44	None
Injection, diphenhydramine hcl, up to 50 mg	14	$14	None

2017: 14 services

Sort by

Original Medicare services billed in 2017

Injection, darbepoetin alfa, 1 microgram (non-esrd use)	14	$38,307	None
Injection, denosumab, 1 mg	14	$31,667	None
Return visit (30+ min)	120	$14,299	$81
Injection, ferric carboxymaltose, 1 mg	18	$11,812	None
Short return visit (20+ min)	121	$11,603	$56
Administration of chemotherapy into vein, 1 hour or less	24	$8,552	$117
Long return visit (40+ min)	27	$3,385	$109
Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	151	$3,125	$10
Injection of drug or substance under skin or into muscle	40	$1,903	$21
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less	16	$1,732	$25
Injection of additional new drug or substance into vein	17	$1,349	$19
Injection of drug or substance into vein	23	$1,111	$46
Injection, dexamethasone sodium phosphate, 1 mg	16	$36	None
Injection, ondansetron hydrochloride, per 1 mg	13	$10	None

Medicaid work

$1,355 in 2019

Medicaid paid $1,355 for 83 billed services this clinician did in 2019, up to 19 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Sort by

Largest Medicaid services in 2019

Return visit (30+ min)	51	$1,211
Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count	32	$144

Sort by

Medicaid work by year

2019	83	2	19	$1,355
2018	15	1	14	$57

See the largest Medicaid services in earlier years

2018

Sort by

Largest Medicaid services in 2018

Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count	15	$57

Drugs they prescribed that Part D paid

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 7% of their 344 Part D prescriptions in 2022. Long-acting opioids: 50% of their opioid prescriptions.

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

Year by year

Sort by

Part D prescribing by year

2023	33	26	None	None	$4,083
2022	344	134	7% (24)	None	$1,573,791
2021	323	144	11% (36)	None	$361,272
2020	282	151	15% (41)	None	$146,528
2019	111	73	26% (29)	20%	$149,762
2018	129	51	None	36%	$360,049
2017	123	54	None	20%	$125,553
2016	357	139	42% (149)	4%	$7,714
2015	73	38	60% (44)	None	$1,596

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2022: 8 drugs

Sort by

Part D drugs prescribed in 2022

Revlimid	50	$870,738	$17,415
Pomalyst	13	$259,807	$19,985
Promacta	16	$243,188	$15,199
Lenalidomide	11	$132,671	$12,061
Abiraterone Acetate	11	$1,220	$111
Acyclovir	16	$567	$35
Hydroxyurea	11	$497	$45
Letrozole	19	$384	$20

2021: 6 drugs

Sort by

Part D drugs prescribed in 2021

Revlimid	13	$213,152	$16,396
Hydroxyurea	18	$814	$45
Hydrocodone-Acetaminophen	15	$299	$20
Letrozole	12	$292	$24
Anastrozole	13	$284	$22
Omeprazole	11	$167	$15

2020: 7 drugs

Sort by

Part D drugs prescribed in 2020

Hydroxyurea	21	$768	$37
Letrozole	17	$414	$24
Hydrocodone-Acetaminophen	22	$381	$17
Klor-Con M20	12	$380	$32
Anastrozole	11	$276	$25
Lidocaine Hcl Viscous	14	$197	$14
Lorazepam	14	$108	$8

2019: 2 drugs

Sort by

Part D drugs prescribed in 2019

Letrozole	11	$498	$45
Hydrocodone-Acetaminophen	14	$172	$12

2018: 1 drug

Sort by

Part D drugs prescribed in 2018

Xarelto	12	$6,856	$571

2017: 3 drugs

Sort by

Part D drugs prescribed in 2017

Meloxicam	21	$883	$42
Warfarin	14	$232	$17
Prochlorperazine Maleate	18	$105	$6

2016: 3 drugs

Sort by

Part D drugs prescribed in 2016

Hydrocodone-Acetaminophen	114	$3,319	$29
Meloxicam	169	$668	$4
Oxycodone-Acetaminophen	12	$575	$48

2015: 2 drugs

Sort by

Part D drugs prescribed in 2015

Hydrocodone-Acetaminophen	36	$900	$25
Meloxicam	25	$101	$4

Money from drug and device companies

$316 in 2023

Sort by

Industry payments by year

2023	7	10	None	$316
2022	2	2	None	$25

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Sort by

Payments by company

Abbvie	Epkinly	$119	1 payment Meals for Epkinly · 2023-06-21 · $119
AstraZeneca Pharmaceuticals LP	Enhertu	$60	3 payments Meals for Imfinzi · 2023-09-15 · $24 Meals for Enhertu · 2023-06-09 · $16 Meals for Enhertu · 2023-05-03 · $20
Janssen Biotech	Imbruvica	$40	2 payments Meals for Imbruvica · 2023-08-22 · $27 Meals for Rybrevant · 2023-06-28 · $13
Takeda Pharmaceuticals U.S.A.	Iclusig	$27	1 payment Meals for Iclusig · 2023-10-10 · $27
Kite Pharma	Yescarta	$26	1 payment Meals for Yescarta · 2023-10-03 · $26
Daiichi Sankyo	Injectafer	$25	1 payment Meals for Injectafer · 2023-03-09 · $25

See all 10 published payments

Sort by

Every published payment

Takeda Pharmaceuticals U.S.A.	Meals · 2023-10-10	Iclusig	$27
Kite Pharma	Meals · 2023-10-03	Yescarta	$26
AstraZeneca Pharmaceuticals LP	Meals · 2023-09-15	Imfinzi	$24
Janssen Biotech	Meals · 2023-08-22	Imbruvica	$27
Eisai	Meals · 2023-08-04	Lenvima	$20
Janssen Biotech	Meals · 2023-06-28	Rybrevant	$13
Abbvie	Meals · 2023-06-21	Epkinly	$119
AstraZeneca Pharmaceuticals LP	Meals · 2023-06-09	Enhertu	$16
AstraZeneca Pharmaceuticals LP	Meals · 2023-05-03	Enhertu	$20
Daiichi Sankyo	Meals · 2023-03-09	Injectafer	$25

See earlier years (2022)

2022: $25

Sort by

Payments by company in 2022

AstraZeneca Pharmaceuticals LP	Enhertu	$13	1 payment Meals for Enhertu · 2022-12-07 · $13
Daiichi Sankyo	Injectafer	$12	1 payment Meals for Injectafer · 2022-10-27 · $12

Professional record

NPI: 1144698721
Licence: CA 52838California C52838: Cancelled
Group: Stanford Health Care
Gender: Female

More record details

Sole proprietor: No
Taxonomy: Physician assistant (363A00000X)
Mailing address: 300 Pasteur Dr, Stanford, CA, 94305
NPI first listed: 2015-09-12
NPI last updated: 2022-09-16
NPI record certified: 2022-09-16

This is when the NPI record was last certified, not a medical board exam.

This office lists an electronic records connection.